Domov › Nemalobunkový karcinóm pľúc › Idaho › Boise
Klinické štúdie Nemalobunkový karcinóm pľúc v meste Boise, ID
14 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v meste Boise a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Prebieha náborFáza 3
- Saint Alphonsus Cancer Care Center-Boise, Boise
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Prebieha náborFáza 3
- Saint Luke's Cancer Institute - Boise, Boise
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Prebieha náborFáza 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Prebieha náborFáza 3
- Research Site, Boise
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Prebieha náborFáza 3
- Saint Alphonsus Regional Medical Center - Boise, Boise
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- St. Luke's Cancer Institute, Boise
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Prebieha náborFáza 3
- Saint Luke's Cancer Institute - Boise, Boise
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Prebieha náborFáza 3
- Saint Alphonsus Health System, Boise
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2/3
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Prebieha náborObservačná štúdia
- Saint Alphonsus Cancer Care Center-Boise, Boise
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, Boise
Štúdie Nemalobunkový karcinóm pľúc v iných mestách
- Houston, TX145 štúdií
- New York City, NY121 štúdií
- Arlington, VA104 štúdií
- Nashville, TN97 štúdií
- Boston, MA90 štúdií
- Los Angeles, CA87 štúdií
- St. Louis, MO73 štúdií
- Chicago, IL61 štúdií
- Baltimore, MD60 štúdií
- San Antonio, TX59 štúdií
- Columbus, OH57 štúdií
- Washington, DC55 štúdií
Iné štúdie v Boise
- Rakovina pľúc11 štúdií
- Akútna myeloidná leukémia8 štúdií
- Rakovina prostaty8 štúdií
- Rakovina hrubého čreva7 štúdií
- Kolorektálny karcinóm6 štúdií
- Syndróm dychovej tiesne6 štúdií
- Rakovina prsníka6 štúdií
- Melanóm6 štúdií
- Burkitov lymfóm5 štúdií
- Rakovina pankreasu4 štúdií
- Myeloproliferatívne neoplázie4 štúdií
- Myelodysplastické syndrómy4 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.